METAREM:Patients with advanced cancer research hub

METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0

This study looks at new treatments for advanced cancers, including a specific lung cancer called NSCLC. It tests two medicines, Keytruda and Libtayo, to see if they can stop cancer from growing and improve patients' lives.